Back to top

Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending

Galmed Pharmaceuticals ( ($GLMD) ) has issued an announcement. Galmed Pharmaceuticals filed a Form 6-K in early July 2026, providing unaudited cond...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Galmed Pharmaceuticals Ltd. (GLMD)